Boston Scientific Stock Steady as Annual Sales Hit $16 Billion

Key Facts

1Boston Scientific achieved fiscal 2025 net sales of approximately $16.0 billion, a 10% increase from 2024.

2The company's operating income rose 20% to $3.0 billion in fiscal 2025, indicating improved profitability.

Amid the ongoing expansion of the global med-tech sector, Boston Scientific reported robust financial results for fiscal year 2025. According to reports, the company achieved net sales of approximately $16.0 billion, marking a 10% increase over the previous year. Operating income also surged by 20% to reach $3.0 billion, driven by strong performance in the Cardiovascular and MedSurg segments, particularly the WATCHMAN structural heart device.

This growth comes at a time when industry peers are experiencing mixed dynamics; market data indicates relatively stable profit margins for major medical device manufacturers. Compared to last year's results, Boston Scientific has significantly improved its operating profitability, strengthening its competitive position against peers who are facing supply chain and manufacturing cost challenges according to industry analysis.

In terms of market performance, BSX stock stood at $44.03 (close July 17, 2026), with daily fluctuations between $43.76 and $45.25. Investors are now monitoring macroeconomic data impacting risk appetite, with the U.S. Consumer Price Index (CPI) release scheduled for July 14, which may influence broader market sentiment for the healthcare sector.